|
Gene: THBS3 |
Gene summary for THBS3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | THBS3 | Gene ID | 7059 |
Gene name | thrombospondin 3 | |
Gene Alias | TSP3 | |
Cytomap | 1q22 | |
Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | F5H4Z8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7059 | THBS3 | PTC06 | Human | Thyroid | PTC | 7.38e-08 | 1.76e-01 | 0.2057 |
7059 | THBS3 | PTC07 | Human | Thyroid | PTC | 2.00e-09 | 5.60e-02 | 0.2044 |
7059 | THBS3 | ATC09 | Human | Thyroid | ATC | 5.00e-17 | 6.80e-01 | 0.2871 |
7059 | THBS3 | ATC11 | Human | Thyroid | ATC | 2.14e-02 | 3.84e-01 | 0.3386 |
7059 | THBS3 | ATC12 | Human | Thyroid | ATC | 1.21e-08 | 1.74e-01 | 0.34 |
7059 | THBS3 | ATC13 | Human | Thyroid | ATC | 5.65e-23 | 5.22e-01 | 0.34 |
7059 | THBS3 | ATC1 | Human | Thyroid | ATC | 1.04e-17 | 7.32e-01 | 0.2878 |
7059 | THBS3 | ATC2 | Human | Thyroid | ATC | 1.04e-12 | 1.11e+00 | 0.34 |
7059 | THBS3 | ATC3 | Human | Thyroid | ATC | 9.68e-05 | 3.02e-01 | 0.338 |
7059 | THBS3 | ATC4 | Human | Thyroid | ATC | 1.50e-11 | 2.16e-01 | 0.34 |
7059 | THBS3 | ATC5 | Human | Thyroid | ATC | 1.89e-34 | 5.77e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0031589111 | Thyroid | PTC | cell-substrate adhesion | 169/5968 | 363/18723 | 2.73e-09 | 7.57e-08 | 169 |
GO:0001503110 | Thyroid | PTC | ossification | 176/5968 | 408/18723 | 9.26e-07 | 1.40e-05 | 176 |
GO:000716020 | Thyroid | PTC | cell-matrix adhesion | 109/5968 | 233/18723 | 1.28e-06 | 1.84e-05 | 109 |
GO:00603486 | Thyroid | PTC | bone development | 90/5968 | 205/18723 | 1.89e-04 | 1.42e-03 | 90 |
GO:003158928 | Thyroid | ATC | cell-substrate adhesion | 195/6293 | 363/18723 | 1.58e-15 | 1.17e-13 | 195 |
GO:000150332 | Thyroid | ATC | ossification | 206/6293 | 408/18723 | 9.23e-13 | 3.95e-11 | 206 |
GO:0007160111 | Thyroid | ATC | cell-matrix adhesion | 128/6293 | 233/18723 | 1.49e-11 | 5.41e-10 | 128 |
GO:006034813 | Thyroid | ATC | bone development | 102/6293 | 205/18723 | 1.18e-06 | 1.52e-05 | 102 |
GO:0060349 | Thyroid | ATC | bone morphogenesis | 50/6293 | 93/18723 | 4.87e-05 | 3.88e-04 | 50 |
GO:00487053 | Thyroid | ATC | skeletal system morphogenesis | 101/6293 | 220/18723 | 9.48e-05 | 6.93e-04 | 101 |
GO:00614484 | Thyroid | ATC | connective tissue development | 112/6293 | 252/18723 | 2.08e-04 | 1.38e-03 | 112 |
GO:0060350 | Thyroid | ATC | endochondral bone morphogenesis | 28/6293 | 54/18723 | 4.27e-03 | 1.80e-02 | 28 |
GO:00352654 | Thyroid | ATC | organ growth | 77/6293 | 178/18723 | 4.45e-03 | 1.85e-02 | 77 |
GO:00512163 | Thyroid | ATC | cartilage development | 81/6293 | 190/18723 | 5.70e-03 | 2.30e-02 | 81 |
GO:00034161 | Thyroid | ATC | endochondral bone growth | 15/6293 | 26/18723 | 9.95e-03 | 3.63e-02 | 15 |
GO:00613831 | Thyroid | ATC | trabecula morphogenesis | 22/6293 | 43/18723 | 1.30e-02 | 4.55e-02 | 22 |
GO:0098868 | Thyroid | ATC | bone growth | 16/6293 | 29/18723 | 1.37e-02 | 4.77e-02 | 16 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
THBS3 | SDC1 | THBS3_SDC1 | THBS | Breast | DCIS |
THBS3 | SDC4 | THBS3_SDC4 | THBS | Breast | DCIS |
THBS3 | CD36 | THBS3_CD36 | THBS | Breast | DCIS |
THBS3 | CD47 | THBS3_CD47 | THBS | Breast | DCIS |
THBS3 | ITGA3_ITGB1 | THBS3_ITGA3_ITGB1 | THBS | CRC | MSI-H |
THBS3 | SDC1 | THBS3_SDC1 | THBS | CRC | MSI-H |
THBS3 | SDC4 | THBS3_SDC4 | THBS | CRC | MSI-H |
THBS3 | CD47 | THBS3_CD47 | THBS | CRC | MSI-H |
THBS3 | ITGA3_ITGB1 | THBS3_ITGA3_ITGB1 | THBS | Esophagus | ESCC |
THBS3 | SDC1 | THBS3_SDC1 | THBS | Esophagus | ESCC |
THBS3 | SDC4 | THBS3_SDC4 | THBS | Esophagus | ESCC |
THBS3 | CD36 | THBS3_CD36 | THBS | Esophagus | ESCC |
THBS3 | CD47 | THBS3_CD47 | THBS | Esophagus | ESCC |
THBS3 | ITGA3_ITGB1 | THBS3_ITGA3_ITGB1 | THBS | HNSCC | OSCC |
THBS3 | SDC1 | THBS3_SDC1 | THBS | HNSCC | OSCC |
THBS3 | SDC4 | THBS3_SDC4 | THBS | HNSCC | OSCC |
THBS3 | CD36 | THBS3_CD36 | THBS | HNSCC | OSCC |
THBS3 | CD47 | THBS3_CD47 | THBS | HNSCC | OSCC |
THBS3 | ITGA3_ITGB1 | THBS3_ITGA3_ITGB1 | THBS | HNSCC | Precancer |
THBS3 | SDC1 | THBS3_SDC1 | THBS | HNSCC | Precancer |
Page: 1 2 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
THBS3 | SNV | Missense_Mutation | rs528865017 | c.362G>A | p.Arg121His | p.R121H | P49746 | protein_coding | deleterious(0.04) | possibly_damaging(0.557) | TCGA-21-1080-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
THBS3 | SNV | Missense_Mutation | novel | c.584N>C | p.Met195Thr | p.M195T | P49746 | protein_coding | deleterious(0.01) | benign(0.039) | TCGA-22-4609-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
THBS3 | SNV | Missense_Mutation | c.1279N>G | p.His427Asp | p.H427D | P49746 | protein_coding | tolerated(1) | benign(0.088) | TCGA-39-5039-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
THBS3 | SNV | Missense_Mutation | c.2116N>C | p.Asp706His | p.D706H | P49746 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-46-6025-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | SD | |
THBS3 | SNV | Missense_Mutation | rs773242038 | c.1419C>A | p.Asp473Glu | p.D473E | P49746 | protein_coding | tolerated(0.41) | benign(0.034) | TCGA-77-8133-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
THBS3 | SNV | Missense_Mutation | novel | c.1024N>A | p.Glu342Lys | p.E342K | P49746 | protein_coding | tolerated(0.17) | possibly_damaging(0.506) | TCGA-90-7767-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
THBS3 | SNV | Missense_Mutation | novel | c.892T>C | p.Tyr298His | p.Y298H | P49746 | protein_coding | deleterious(0.03) | possibly_damaging(0.497) | TCGA-F7-A624-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
THBS3 | SNV | Missense_Mutation | c.2171C>A | p.Thr724Lys | p.T724K | P49746 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-QK-A64Z-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
THBS3 | SNV | Missense_Mutation | novel | c.2816C>A | p.Thr939Lys | p.T939K | P49746 | protein_coding | deleterious(0.02) | possibly_damaging(0.551) | TCGA-UF-A7JF-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR |
THBS3 | SNV | Missense_Mutation | novel | c.1768G>C | p.Asp590His | p.D590H | P49746 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-J4-AATZ-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Hormone Therapy | eligard | PD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |